Advertisement

Melatonin plays critical role in mesenchymal stem cell-based regenerative medicine in vitro and in vivo

  • Chenxia Hu
  • Lanjuan LiEmail author
Open Access
Review
  • 284 Downloads

Abstract

Although stem cells have emerged as promising sources for regenerative medicine, there are many potential safety hazards for their clinical application, including tumorigenicity, an availability shortage, senescence, and sensitivity to toxic environments. Mesenchymal stem cells (MSCs) have various advantages compared to other stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs); thus, MSCs have been intensely investigated in recent studies. However, they are placed in a harsh environment after isolation and transplantation, and the adverse microenvironment substantially reduces the viability and therapeutic effects of MSCs. Intriguingly, melatonin (MT), which is primarily secreted by the pineal organ, has been found to influence the fate of MSCs during various physiological and pathological processes. In this review, we will focus on the recent progress made regarding the influence of MT on stem cell biology and its implications for regenerative medicine. In addition, several biomaterials have been proven to significantly improve the protective effects of MT on MSCs by controlling the release of MT. Collectively, MT will be a promising agent for enhancing MSC activities and the regenerative capacity via the regulation of reactive oxygen species (ROS) generation and the release of immune factors in regenerative medicine.

Keywords

Melatonin Mesenchymal stem cell Regenerative medicine In vitro In vivo Protection Therapy 

Abbreviations

AFMK

N1-acetyl-N2-formyl-5-methoxykynuramine

AIC

Acute interstitial cystitis

AMK

N1-acetyl-5-methoxykynuramine

b-FGF

Basic fibroblast growth factor

BMP2

Bone morphogenetic protein 2

CA

Calcium aluminate

CCl4

Carbon tetrachloride

CuZnSOD

Copper, zinc superoxide dismutase

DN

Diabetic nephropathy

ERK1/2

Extracellular signal-regulated kinase 1 and 2

FAK

Focal adhesion kinase

GAG

Glycosaminoglycan

H2O2

Hydrogen peroxide

HGF

Hepatocyte growth factor

IL

Interleukin

ISCT

International Society for Cellular Therapy

LPL

Lipoprotein lipase

Mel-NPs

Melatonin nanoparticles

MMPs

Matrix metalloproteinases

MnSOD

Manganese superoxide dismutase

MSCs

Mesenchymal stem cells

MT

Melatonin

NOS

Nitric oxide synthase

P38MAPK

P38 mitogen-activated protein kinase

PLGA

Poly (lactic-co-glycolic acid)

PLGA-mPEG

Poly(lactide-co-glycolide)-monomethoxy-poly-(polyethylene glycol)

PPARγ

Peroxisome proliferator-activated receptor gamma

PrPC

Prion protein

ROS

Reactive oxygen species

RUNX2

Runt-related transcription factor 2

SBIR

Small bowel ischemia-reperfusion

SIRT1

Sirtuin 1 deacetylase

TNF

Tumor necrosis factor

VEGF

Vascular endothelial growth factor

Background

Recently, mesenchymal stem cells (MSCs) have emerged as promising sources for restoring tissue and organ function; however, there are many potential safety hazards for their clinical application, including an availability shortage, senescence, sensitivity to toxic environments, and potential tumorigenicity. Moreover, heterogeneity exists in the isolation and cultivation procedures among laboratories, and the definition of MSCs remains unclear according to current comments from Sipp et al. [1]. Herein, we termed MSCs according to the criteria from the International Society for Cellular Therapy (ISCT). (i) MSCs must be plastic-adherent when maintained in standard culture conditions. (ii) MSCs must express CD105, CD73, and CD90 and lack expression of CD45, CD34, CD14, or CD11b; CD79alpha or CD19; and HLA-DR surface markers. (iii) MSCs must differentiate in vitro into osteocytes, chondrocytes, and adipocytes [2]. Although the nature and functions of MSCs remain unclear, nonclonal stromal cultures obtained from the bone marrow and other tissues that contain a subpopulation of stem cells are currently serving as sources of putative MSCs for therapeutic purposes, largely due to findings that they might be effective in the treatment of several diseases [3]. In addition, MSC-based treatment is powerful and can regenerate organ function through the secretion of cytokines and other anti-inflammatory mechanisms [4]. However, various adverse factors in vitro and in vivo will reduce the stemness of MSCs and commonly hinder the differentiation process of MSCs. Once MSCs are isolated from their original tissues or organs, they rapidly lose their vitality because of inappropriate ex vivo conditions, and shortened telomerase activity and disturbance of the secretome also disturb their morphology [5]. Long-term in vitro culture leads to a decreased colony-forming capacity, reduced proliferation ability, unstable cellular DNA, and a shortened cell lifespan [6, 7]. A sufficient number of active MSCs can compensate for missing organ functions induced by wound, ischemia, drugs, high glucose, sepsis, etc. [8, 9, 10, 11, 12]; however, the in vitro life span of MSCs is limited by the harsh microenvironment, which thus leads to an insufficient cell source [6]. On the other hand, transplanted MSCs can secrete beneficial cytokines within the injured area, while more than 80–90% of implanted cells are sentenced to apoptosis or death 72 h after injection by the harsh microenvironment in vivo [13]. Moreover, transplantation of MSCs decreases their survival and proliferation rates because the low blood supply and collagen density of tissue cannot provide sufficient nutrition or growth factors; concurrently, oxidative stress and chronic inflammation are substantially increased and impair MSC activities in vivo [14].

Under physiological conditions, MSCs will undoubtedly produce basal reactive oxygen species (ROS) to maintain cell proliferation and differentiation, while incomplete oxidation of oxygen in vitro and in vivo results in excessive production of ROS and DNA damage in MSCs and impairs the normal function of MSCs via multiple apoptosis-related pathways [15, 16]. Extremely high ROS levels generated by hydrogen peroxide (H2O2), hydroxyl radicals, and superoxide anion will induce oxidative stress in MSCs [17]. The excessive ROS induced by a stressful microenvironment impairs the self-renewal, proliferation, and differentiation capacity of MSCs [18]; moreover, aging significantly upregulates the level of oxidative stress and thus limits the quantity and quality of MSC daughter cells [19]. Recently, melatonin (MT) has been isolated from the pineal organ and shown to participate in regulating multiple physiological functions, including sleep promotion, circadian rhythms, and neuroendocrine processes [20, 21]. The administration of MT substantially improves the manipulation advantages of MSCs ex vivo and in vivo; in general, MT serves as a component of the homeostatic and cell-protective agents, which protect MSCs from oxidation, inflammation, apoptosis, ischemia, and aging for regulating MSC differentiation and protection in different organs and tissues [22, 23]. The antioxidant capacity of MSCs could be particularly relevant in the case of immune and inflammatory components. Importantly, MT is involved in the detoxification of ROS and free radical intermediates because it plays a critical role in the release of antioxidant enzymes, including catalase, glutathione reductase, superoxide dismutase, and glutathione peroxidase [24, 25]. In this article, we review the current literature on the regulatory effects of MT on MSCs undergoing oxidative stress and differentiation; we also discuss its protective effects to improve the therapeutic potential of MSCs in different disease models. In addition to general treatment, several biomaterials emerge for controlling the release of MT, which significantly improves the protective effects of MT on MSCs. Thus, MT has emerged as a novel and potential modulator of MSC fate in vitro and in vivo (Fig. 1). In the near future, MT will be a promising agent for controlling MSC fate via the regulation of ROS generation and release of immune factors in regenerative medicine.
Fig. 1

MT has emerged as a novel and potential modulator of MSC fate in vitro and in vivo

MT and related agents are promising factors that participate in MSC biology

Mammals secrete a low level of MT during the daytime, and the basal level is lower than 10 pg/mL, while the level of MT is adjusted to higher values (up to 120 pg/mL) at night [26]. MT is not only a hormone secreted by the pineal gland but can also be synthesized by other tissues, including the retina, harderian gland, gastrointestinal tract, testes, and lymphocytes [27]. MT is hypothesized to originate from the mitochondria of eukaryotic cells [28, 29]; it has been demonstrated that the MT concentration is highest in the cell membrane, followed by the mitochondria, nucleus, and cytosol, at the cellular level [30]. Given that mitochondria are the major target of free radicals and the primary intracellular ROS-producing organelle, the lipophilicity of MT is beneficial for exerting its protective effects in vivo [31]. Due to its detoxification and anti-inflammatory properties, MT rescues mitochondrial dysfunction [32], cellular senescence [33], and aging [34, 35]. With respect to energy metabolism, MT significantly upregulates the level of mitochondrial respiration and ATP production, while it inhibits mitochondrial permeability transition pores through the activation of copper, zinc superoxide dismutase (CuZnSOD) within the intermembrane space [29, 36, 37].

Although MT effectively exerts broad free radical scavenging activity without receptors in vivo, the antioxidant activity of MT also requires assistance from specific receptors [38, 39]. Two specific G-protein-coupled receptors, MT1 and MT2 in mammals, bind calmodulin and consequently activate nitric oxide synthase (NOS) [40] and participate in regulating the functions of MSCs [31, 41]. Aside from these two main receptors, MT also interacts with other receptors, including the nonmammalian MT receptor subtype MT3, the nuclear receptor ROR/RZR, and calmodulin [42, 43]. However, the detailed expression level of MT receptors should be determined according to the stem cell type and the physiological status of stem cells. For example, MT stimulates MT1 in cultured placenta-derived MSCs, but not MT2, to increase the cell proliferation and survival rate and further enhance the degree of neuronal differentiation [44]. MSCs isolated from adolescent idiopathic scoliosis patients express lower levels of MT2 and demonstrate lower expression levels of osteogenic and chondrogenic markers than MSCs derived from control healthy individuals after MT treatment [45]. Thus, the MT receptor-dependent pathway also plays a critical role in enhancing MSC stemness and differentiation in regenerative medicine.

MT and its derivatives scavenge free radicals generated from aerobic metabolism and oxidative stress via single-electron transfer, hydrogen transfer, and radical adduct formation [46, 47]. MT can be metabolized into several derivatives, including N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK), N1-acetyl-5-methoxykynuramine (AMK), 6-hydroxymelatonin, 2-hydroxymelatonin, 3-hydroxymelatonin, and cyclic 3-hydroxymelatonin [47, 48]. In addition, special receptor antagonists and agonists neutralize the effects of MT on MSCs, which further helps us untangle the underlying protective mechanisms. Luzindole, which serves as a common nonselective antagonist of MT receptors, activates the MEK/ERK pathway to antagonize the anti-adipogenesis effect of MT on MSCs [49] and blocks the MT-mediated anti-senescence effect [9]. Under the stimulation of MT receptor antagonists, including luzindole and 4P-PDOT, an MT-induced increase in alkaline phosphatase (ALP) activity is highly inhibited, and MT-promoted MSC osteogenesis is thus decreased [50]. Multiple synthetic agonists, including TIK-301, piromelatine, GG-012, AH-001, AH-017, agomelatine, ramelteon, GR 196429, MA-2, tasimelteon, UCM765, and UCM924, regulate circadian rhythms [51]; however, whether these agonists cooperate with MT to protect MSCs from injury remains unknown.

MT can exert different effects on MSCs in vitro

As the microenvironment is very important to MSCs under in vitro culture, the MSC fate is finely regulated by the surrounding mechanical and molecular signals; thus, MT may act as a protective agent and participate in the regulation of MSC fate. Although ROS act as dangerous toxicants under pathological conditions, MT upregulates CuZnSOD and manganese superoxide dismutase (MnSOD) expression levels and downregulates Bax expression, consequently improving MSC activities, and it reduces ROS production in a dose-dependent manner [52]. MT is an effective agent to alleviate the apoptotic factors for protecting MSCs from injury, while it also acts as an inhibitory agent or a promotive agent according to the MSC differentiation fate (Table 1).
Table 1

MT is an effective agent to alleviate the apoptotic factors for protecting MSCs from injury, while it also acts as an inhibitory agent or a promotive agent according to MSC differentiation fate

Concentration

Time point

MSC resource

Effect

Mechanism

Ref

10 nM, 1 μM, 100 μM

Cotreatment

Bone marrow

No effect on the proliferation of MSCs, inhibits adipogenic differentiation of MSCs, enhances MSC osteogenic differentiation

PPARc expression↓, Runx2 expression↑

[49]

50 nM

Cotreatment

Adipose

Increases the ALP expression

MT2 receptor↑, MEK/ERK (1/2) ↑

[50]

10 nM, 1 μM, 100 μM

Cotreatment

Synovium

Improves the proliferation of MSCs, protects cell viability in the presence of IL-1β, promotes MSC osteogenic differentiation when exposed to IL-1β

SOD↑

[52]

1 μM, 10 μM, 100 μM

Cotreatment

Adipose

Reduces the senescent progress and abnormal activation of autophagy

AKT↑, ROS↓

[53]

50 μM, 100 μM

Post-treatment

Bone marrow

Reduces cell death of MSCs

AMPK↑, acetyl-CoA carboxylase↑

[54]

1 μM

Pretreatment

Adipose

Enhances MSC proliferation and self-renewal and diminishes the extent of MSC apoptosis

PrPC-dependent pathway↑

[55]

10–300 nM

Pretreatment

Bone marrow

Protects against hypoxia/serum deprivation-induced injury

ERK1/2↑

[56]

5 μM

Pretreatment

Bone marrow

Prevents MSC apoptosis

Mitogenic factors↑

[57]

10 nM, 1 μM, 100 μM

Post-treatment

Bone marrow

Reverses H2O2-induced senescence

P38MAPK↓, p16INK4α↓, SIRT1↑

[59]

10 nM, 1 μM, 100 μM

Post-treatment

Bone marrow

Restores the impaired differentiation ability of MSCs induced by H2O2

SIRT1↑

[59]

10 nM, 1 μM, 100 μM

Pretreatment

Bone marrow

Maintains the morphology, viability, and osteogenic differentiation ability of MSCs

ROS↓, p53/ERK/p38↓

[61]

50 nM

Cotreatment

Bone marrow

Inhibits adipogenic differentiation of MSCs at the early stage of adipogenic differentiation

ROS↓, phosphorylating ERK/GSK-3β↓

[62]

50 nM

Cotreatment

Bone marrow

Promotes chondrogenic differentiation of MSCs

MT receptor-dependent pathway↑

[63]

50 nM

Cotreatment

Bone marrow

Restores the pellet size and matrix accumulation, upregulates chondrogenic differentiation of MSCs, reduces cell apoptosis during the whole chondrogenesis

IL-1β-induced activation of NF-κB signaling↓

[64]

1 μM

Cotreatment

Synovium

Rescues the IL-1β and TNF-α impaired chondrogenesis of MSCs

ROS↓, SOD↑, MMPs↓

[65]

10 μM, 50 μM, 100 μM, 200 μM

Pretreatment

Adipose

Rescues MSCs from cell death induced by oxidative stress; 100 μM of MT confers greater cytoprotection on MSCs than 200 μM

ROS↓, P38MAPK↓, harmful inflammatory cytokines↓

 

MT serves as a protective agent, promotive agent, or inhibitory agent in MSC physiological and pathological processes in vitro

p-Cresol was found to be substantially higher in chronic kidney failure patients than in healthy individuals; it also reduced the proliferation of MSCs in a dose-dependent manner, while pretreatment with MT on MSCs significantly reduced the senescent progress and abnormal activation of autophagy by activating the AKT signaling pathway and inhibiting ROS accumulation [53]. Although tissue-engineered heart valves serve as effective biological materials for repairing congenital cardiac valve diseases, the high flow shear stress significantly reduces the therapeutic effects of MSCs, while MT significantly reduces the cell death of MSCs under a shear stress condition in a concentration-dependent manner by upregulating the phosphorylation of AMPK and acetyl-CoA carboxylase [54]. MT pretreatment enhanced MSC proliferation and self-renewal and diminished the extent of MSC apoptosis in oxidative stress conditions in a prion protein (PrPC)-dependent manner [55]. MT pretreatment upregulates p38MAPK and extracellular signal-regulated kinase 1 and 2 (ERK1/2) phosphorylation levels in MSCs and thus protects against hypoxia/serum deprivation-induced injury [56]. Pretreatment with MT decreases H2O2-induced apoptosis by attenuating ROS generation; partially inhibiting the activation of p38 mitogen-activated protein kinase (P38MAPK) signaling molecule; increasing the release of mitogenic factors, including basic fibroblast growth factor (b-FGF) and hepatocyte growth factor (HGF); and reducing the production of harmful inflammatory cytokines, including tumor necrosis factor (TNF)-α and interleukin (IL)-6 [57, 58]. Zhou et al. demonstrated that pretreatment with MT does not decrease H2O2-induced premature senescence, while treatment with MT subsequent to H2O2 exposure effectively reversed the premature senescence in a dose-dependent manner by downregulating p38MAPK phosphorylation and senescence-associated protein p16INK4α and increasing the expression level of sirtuin 1 deacetylase (SIRT1) [59]. To this end, the time point of MT administration is also important for the precise protective effects on MSCs in vitro.

MT promotes MSC osteogenesis and chondrogenesis and inhibits adipogenesis

In addition, MT can not only influence MSC activities ex vivo but also influence the differentiation abilities, particularly osteogenesis. Radio et al. first showed that the addition of MT at a concentration of 50 nM into osteogenic medium increased the ALP expression level to a certain extent in MSCs via upregulating the MT2 receptor and the MEK/ERK (1/2) signaling pathway [50]. Moreover, MSCs were cultured in osteogenic differentiation medium with IL-1β for 21 days, and 1 μM MT significantly increased the levels of type I collagen, ALP, and osteocalcin, while 100 μM MT treatment yielded the highest level of osteopontin [52]. The addition time point of MT exposure will certainly influence the final differentiation fate of MSCs, as it was demonstrated that the addition of MT at the initiation stage or the end stage of osteogenesis increases the rate of mature cells, while addition at the intermediate stage does not influence the outcome [60]. Moreover, H2O2-induced premature senescence and an iron overload microenvironment resulted in a decreased osteogenic differentiation potential, and MT restored the impaired differentiation ability of MSCs by upregulating the SIRT1-dependent pathway and blocking p53/ERK/p38 signaling, respectively [59, 61].

Despite the promotive effects on MSC osteogenesis, MT can exert completely opposite effects on MSC adipogenesis in vitro. MT enhances MSC osteogenesis by upregulating the expression levels of RUNX2, osteopontin, and osteocalcin and inhibits adipogenesis in the same population by suppressing peroxisome proliferator-activated receptor gamma (PPARγ), leptin, lipoprotein lipase (LPL), adiponectin, and adipocyte protein 2 expression [49]. In addition, MT inhibits the adipogenic differentiation of MSCs by regulating the expression level of C/EBPβ at the early stage of adipogenic differentiation, consequently reducing cyclic adenosine monophosphate synthesis by reducing ROS generation and phosphorylating ERK/GSK-3β [62].

Go et al. also proposed that MT promoted chondrogenic differentiation of MSCs because they observed higher levels of chondrogenic markers and more cartilage tissue and collagen isotypes in the MT group than in the control group partially through MT receptors [63]. While IL-1β clearly impaired the chondrogenesis of human MSCs, cotreatment with MT significantly restored the pellet size and matrix accumulation, upregulated the expression levels of chondrogenic markers, maintained the metabolic balance, and reduced cell apoptosis during the whole chondrogenesis by attenuating the IL-1β-induced activation of NF-κB signaling [64]. Similarly, proinflammatory cytokines, including IL-1β and TNF-α, impair the chondrogenesis of MSCs and resulted in cartilage degradation; however, it can be rescued by MT treatment because it can significantly decrease the ROS level, preserve SOD, and suppress the expression levels of matrix metalloproteinases (MMPs) [65].

In this scenario, MT seems to not only drive the commitment and differentiation of MSCs under specific culture conditions but also repair impaired differentiation induced by a harsh microenvironment through regulating paracrine signaling pathways and controlling the ROS level. Moreover, it is necessary to explore the effects of MT in vitro on other differentiation directions in addition to osteogenesis, chondrogenesis, and adipogenesis.

MT significantly improves the therapeutic effects of MSCs in vivo

Harsh in vivo microenvironments effectively weaken the therapeutic effect of MSC-based treatment. In recent years, MT has also emerged as an effective agent for increasing the survival rate of MSCs and provoking a synergistic effect to rescue the function of multiple organs by alleviating inflammation, apoptosis, and oxidative stress (Table 2). MT is widely used to improve the homing ability and decrease the apoptosis rate of MSCs after transplantation in large organs, such as the brain, heart, liver, and kidney (Fig. 2), and the other organs targeted for tissue engineering include the skin, pancreas, small bowel, and limb.
Table 2

MT enhances MSC activity to rescue the function of multiple organs by alleviating inflammation, apoptosis, and oxidative stress

Animal

Disease

Dose

MSC resource

Effect

Mechanism

Ref

C57BL/6a mice

Myocardial infarction

5 μM

Adipose

Heart function↑

SIRT1↑

[14]

Male ICR mice

Skin wound

1 μM

Umbilical cord blood

Wound closure↑; granulation↑; re-epithelialization↑

MT2-mediated pathway↑

[8]

Adult male Sprague Dawley rats

Focal cerebral ischemia

0.05 to 1 mM

Bone marrow

Brain infarction↓; neurobehavioral outcomes↑

ERK1/2 ↑

[9]

Adult male Sprague Dawley rats

Liver fibrosis

5 μM

Bone marrow

Glycogen storage↑; collagen and lipid accumulation↓

TGF-β1 and Bax/Bcl2↓

[10]

Male albino rats

Diabetes

10 mg/kg for 8 weeks

Bone marrow

Structural and functional efficiency of β-cells in the pancreas↑

Antioxidant↑

[11]

Adult male Sprague Dawley rats

Acute kidney injury

After the procedure, 20 mg/kg at 30 min, 50 mg/kg at 6 h and 18 h

Adipose

Sepsis induced acute kidney injury↓

Inflammation↓, inappropriate immune response↓, ROS generation↓, oxidative stress↓

[12]

Male BALB/c nude mice

Limb ischemia

After procedure, 20 mg/kg/day for 28 days

Adipose

MSC functionality↑; neovascularization↑

PrPC expression↑

[55]

Adult male Sprague Dawley rats

Small bowel ischemia reperfusion

After the procedure: 20 mg/kg, 50 mg/kg at 6 h and 18 h

Adipose

Ischemia reperfusion injury↓

Inflammation↓, oxidative stress↓, apoptosis↓, mitochondrial damage↓, DNA damage↓, antioxidant enzymes↑

[66]

Adult male Sprague Dawley rats

Acute interstitial cystitis

After the procedure, 20 mg/kg at 30 min, 50 mg/kg at 6 h and 18 h

Adipose

Cyclophosphamide-induced acute interstitial cystitis↓

Antioxidants↑

[67]

Adult male Wistar strain Albino rats

Diabetic nephropathy

5 μM

Bone marrow

Kidney functions↑

Pathogenic factors↓, autophagy↑

[68]

Fig. 2

MT increases MSC activities to repair functions of large organs, such as the brain, heart, liver, and kidney

MSCs are widely used in the treatment of wound-induced injury and ischemia injury in various tissues, and MT has been applied to improve the therapeutic effects of MSCs via anti-inflammation and antioxidative stress. Pretreatment with MT improved the MSC motility and enhanced the granulation and re-epithelialization of transplanted cells in a mouse skin excisional wound model via an MT2-mediated pathway. Thus, although MT induced the phosphorylation of focal adhesion kinase (FAK) and paxillin, increased the levels of active Cdc42 and Arp2/3, and stimulated cytoskeletal reorganization-related proteins, such as profilin-1, cofilin-1, and F-actin, in MSCs, a lack of MT2 in MSCs during a mouse skin transplantation experiment resulted in impaired wound healing and less engraftment of MSCs at the wound site [8]. In the ischemic brain, MT pretreatment substantially increased the survival of MSCs in vitro and reduced their apoptosis after transplantation in vivo. The MT-pretreated MSCs significantly upregulated angiogenesis, neurogenesis, and the expression of vascular endothelial growth factor (VEGF), which thus reduced brain infarction and improved neurobehavioral outcomes in the animal models via ERK1/2 signaling pathway activation [9]. Similarly, MT effectively improved the survival rate of MSCs and provoked MSCs to restore heart function by activating the SIRT1 signaling pathway and alleviating inflammation, apoptosis, and oxidative stress in the infarcted heart [14]. The combination of MSCs and MT decreased the circulating levels of TNF-α, MPO, LyG6+ cells, CD68+ cells, and WBC count; the gut permeability; and the ischemic mucosal damage score in small bowel ischemia-reperfusion (SBIR) rats [66]. After transplantation into a hind-limb ischemia murine model, MT-pretreated MSCs decreased the number of local apoptotic cells and improved the blood flow perfusion, limb salvage, and vessel regeneration to restore limb function through the upregulation of PrPC expression [55]. The authors suggested that-MT pretreated MSCs would provide a powerful tool for promoting neovascularization in patients suffering from ischemic diseases.

In animal studies, various toxicants have been applied to mimic diseases in humans to further clarify the underling mechanisms and potential effective treatments. To improve the therapeutic effects of MSCs in the treatment of carbon tetrachloride (CCl4)-induced liver injury, MT-pretreated MSCs significantly increased the level of glycogen storage and decreased the level of collagen and lipid accumulation in the injured liver after MSC transplantation [10]. Moreover, although MT did not exert effects on collagen deposition, tissue disruption, and fatty accumulation, it significantly downregulated the expressions of TGF-β1 and Bax and upregulated the expressions of MMPs and Bcl2 in the injured liver [10]. The combined regimen of MT and MSCs was superior than either alone in protecting against cyclophosphamide-induced acute interstitial cystitis (AIC) rats as it significantly reduced the severity of hematuria, release of inflammatory cytokines, glycosaminoglycan, oxidized protein, and ROS in the bladder tissue and improved the integrity of the epithelial layer and area of collagen deposition [67].

As diabetes is a type of chronic disease with a high mortality, it also brings out multiple complications that influence the survival quality of humans. Thus, MSC transplantation is also taken into account for one of the effective treatments for diabetes. The cotreatment of MSCs and MT significantly improved the levels of glucose, insulin, total antioxidant, and malondialdehyde and reduced the number of damaged β-cells in diabetic rats compared with the MSC group alone [11]. Diabetic nephropathy (DN) is one of the microvascular complications of diabetes that may progress to a serious end-stage renal failure. Pretreatment with MT also well-maintained the kidney functions of DN pathogenesis accompanied by higher levels of SOD-1 and Beclin-1 and a lower level of TGF-β in the kidney tissue than in the MSC group [68].

Sepsis is a type of systemic inflammatory response syndrome in response to documented infection in the blood, sputum, urine, or normally sterile body fluid. Sepsis can progress to multiple organ dysfunction and death [69]. Intriguingly, Chen et al. used the combination of MT with apoptotic adipose-derived MSCs and found that the combination provided additional benefits in ameliorating sepsis-induced acute kidney injury through the activation of antioxidative pathways, inhibition of the inflammatory response, and reduction of apoptosis and fibrosis [12]. These findings raise the potential strategy for treating sepsis-induced injury in other organs via the combination of MT and MSCs.

Biomaterials for enhancing the protective effect of MT on MSCs

Currently, various preconditioning strategies are applied in stem cell therapy to provide resistance against injury and enhance the antioxidant capability after MSC implantation. In addition to interaction with growth factors derived from MSCs, the interaction of MT with biomaterials can vigorously improve the therapeutic effects of regenerative medicine. Zhang et al. encapsulated MT into poly (lactic-co-glycolic acid) (PLGA) microspheres (PLGA-MEL-MS) for the sustained release of MT; PLGA-MEL-MS had no apparent effect on the proliferation of human MSCs, while it enhanced the expression levels of runx2, osteopontin, and osteocalcin and enhanced the calcium deposit of human MSCs compared to the control group [70]. To enhance the osteoinductive and osteoconductive properties of calcium aluminate (CA) scaffolds, a system that consists of MT and CA scaffolds has been demonstrated to enhance the adhesion, viability, and proliferation of human osteoblast cells but not that of NIH3T3 fibroblasts; it also promoted the osteogenesis of MSCs into osteoblasts over 14 days [71]. Given that MT is an excellent agent to regulate the fate of MSCs, Lai et al. constructed a device, namely, Chi/Gel multilayer-coated melatonin-loaded TiO2 nanotube substrates, to control the sustained release of melatonin; they found that the sustained release of melatonin could improve the cell proliferation rate and osteoblastic differentiation of MSCs [72]. Nano drug delivery carriers are easy to control the release of drug with polymer membranes, which thus improves the bioavailability of drugs and reduces the required dosage and side effects of drugs. Poly(lactide-co-glycolide)-monomethoxy-poly-(polyethylene glycol) (PLGA-mPEG) nanoparticles were used to encapsulate melatonin and generated melatonin nanoparticles (Mel-NPs). Ma et al. found that Mel-NPs reduced the formation of the p53-cyclophilin D complex, prevented mitochondrial permeability transition pores from opening, improved the MSC survival rates, and rescued MSCs from hypoxia/reoxygenation injury in a controlled manner [73]. Pretreatment with Mel-NPs also improved the MSC survival rates compared with MT in rat myocardial infarction areas and improved the therapeutic effects of MSCs [73]. Thus, the combination of Mel-NPs and stem cell transplantation may be a promising strategy for myocardial infarction therapy. Moreover, the combination of nanomaterial and other new biomaterial with MT may be a novel preconditioning method to improve the efficiency of MSC transplantation.

Conclusion

The excessive ROS during proliferation and differentiation in vitro and the injured microenvironment in vivo significantly reduce the therapeutic effects of MSCs for repairing injury in vivo. MT is a hormone with myriad biological functions, including but not limited to anti-inflammation, oncostatis, circadian and endocrine rhythm regulation, and tumor inhibition. Current evidence has demonstrated that MT can reduce the release of inflammatory cytokines, enhance the proliferation capacity of MSCs, and eliminate the apoptosis of MSCs in vitro and in vivo. Furthermore, as MT is progressively becoming an attractive agent for the regeneration of various organs or tissues, we highlighted that MT regulated the expression of ROS-generating and antioxidant genes as upstream events in its protective and anti-apoptotic mechanisms of MSCs according to the current evidence. In addition, MT has been proven to promote MSC osteogenesis and chondrogenesis and inhibit adipogenesis, and it may be further added as an effective agent in the differentiation medium. After the optimal concentration and optimal administration time point are determined, the protective effects of MT on MSCs can be improved in the near future. It is worth noting that high MT concentrations may harm the epigenetic and genetic stability of MSCs. We believe that the clarification of the underlying mechanisms for eliminating injury in more disease models or patients will shed light on the protective effects of MT on MSC-based cell and tissue engineering.

Notes

Acknowledgements

Not applicable.

Funding

This work was supported by the National Natural Science Foundation of China (No.: 81700553), the Stem Cell and Translational Research, the National Key Research and Development Program of China (No. 2016YFA0101001), and the Postdoctoral Research Foundation China (No. 2017 M183789).

Availability of data and materials

Not applicable.

Authors’ contributions

CH drafted the manuscript and revised the manuscript. LL contributed to manuscript conception. CH and LL provided the financial support. Both authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors consent to the publication of this manuscript.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Sipp D, Robey PG, Turner L. Clear up this stem-cell mess. Nature. 2018;561(7724):455–7.  https://doi.org/10.1038/d41586-018-06756-9.CrossRefPubMedGoogle Scholar
  2. 2.
    Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.  https://doi.org/10.1080/14653240600855905.CrossRefPubMedGoogle Scholar
  3. 3.
    Galderisi U, Giordano A. The gap between the physiological and therapeutic roles of mesenchymal stem cells. Med Res Rev. 2014;34(5):1100–26.  https://doi.org/10.1002/med.21322.CrossRefPubMedGoogle Scholar
  4. 4.
    Rodriguez-Lozano FJ, Garcia-Bernal D, Ros-Roca Mde L, Alguero Mdel C, Onate-Sanchez RE, Camacho-Alonso F, Moraleda JM. Cytoprotective effects of melatonin on zoledronic acid-treated human mesenchymal stem cells in vitro. J Craniomaxillofac Surg. 2015;43(6):855–62.  https://doi.org/10.1016/j.jcms.2015.04.012.CrossRefPubMedGoogle Scholar
  5. 5.
    Farahzadi R, Fathi E, Mesbah-Namin SA, Zarghami N. Anti-aging protective effect of L-carnitine as clinical agent in regenerative medicine through increasing telomerase activity and change in the hTERT promoter CpG island methylation status of adipose tissue-derived mesenchymal stem cells. Tissue Cell. 2018;54:105–13.  https://doi.org/10.1016/j.tice.2018.08.012.CrossRefPubMedGoogle Scholar
  6. 6.
    Danisovic L, Oravcova L, Krajciova L, Varchulova Novakova Z, Bohac M, Varga I, Vojtassak J. Effect of long-term culture on the biological and morphological characteristics of human adipose tissue-derived stem cells. J Physiol Pharmacol. 2017;68(1):149–58.PubMedGoogle Scholar
  7. 7.
    Shuai Y, Liao L, Su X, Yu Y, Shao B, Jing H, Zhang X, Deng Z, Jin Y. Melatonin treatment improves mesenchymal stem cells therapy by preserving stemness during long-term in vitro expansion. Theranostics. 2016;6(11):1899–917.  https://doi.org/10.7150/thno.15412.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lee SJ, Jung YH, Oh SY, Yun SP, Han HJ. Melatonin enhances the human mesenchymal stem cells motility via melatonin receptor 2 coupling with galphaq in skin wound healing. J Pineal Res. 2014;57(4):393–407.  https://doi.org/10.1111/jpi.12179.CrossRefPubMedGoogle Scholar
  9. 9.
    Tang Y, Cai B, Yuan F, He X, Lin X, Wang J, Wang Y, Yang GY. Melatonin pretreatment improves the survival and function of transplanted mesenchymal stem cells after focal cerebral ischemia. Cell Transplant. 2014;23(10):1279–91.  https://doi.org/10.3727/096368913x667510.CrossRefPubMedGoogle Scholar
  10. 10.
    Mortezaee K, Khanlarkhani N, Sabbaghziarani F, Nekoonam S, Majidpoor J, Hosseini A, Pasbakhsh P, Kashani IR, Zendedel A. Preconditioning with melatonin improves therapeutic outcomes of bone marrow-derived mesenchymal stem cells in targeting liver fibrosis induced by CCl4. Cell Tissue Res. 2017.  https://doi.org/10.1007/s00441-017-2604-1.
  11. 11.
    Kadry SM, El-Dakdoky MH, Haggag NZ, Rashed LA, Hassen MT. Melatonin improves the therapeutic role of mesenchymal stem cells in diabetic rats. Toxicol Mech Methods. 2018;28(7):529–38.  https://doi.org/10.1080/15376516.2018.1471634.CrossRefPubMedGoogle Scholar
  12. 12.
    Chen HH, Lin KC, Wallace CG, Chen YT, Yang CC, Leu S, Chen YC, Sun CK, Tsai TH, Chen YL, et al. Additional benefit of combined therapy with melatonin and apoptotic adipose-derived mesenchymal stem cell against sepsis-induced kidney injury. J Pineal Res. 2014;57(1):16–32.  https://doi.org/10.1111/jpi.12140.CrossRefPubMedGoogle Scholar
  13. 13.
    Liu XB, Wang JA, Ogle ME, Wei L. Prolyl hydroxylase inhibitor dimethyloxalylglycine enhances mesenchymal stem cell survival. J Cell Biochem. 2009;106(5):903–11.  https://doi.org/10.1002/jcb.22064.CrossRefPubMedGoogle Scholar
  14. 14.
    Han D, Huang W, Li X, Gao L, Su T, Ma S, Liu T, Li C, Chen J, Gao E, et al. Melatonin facilitates adipose-derived mesenchymal stem cells to repair the murine infarcted heart via the sirt1 signaling pathway. J Pineal Res. 2016;60(2):178–92.  https://doi.org/10.1111/jpi.12299.CrossRefPubMedGoogle Scholar
  15. 15.
    Jeong SG, Cho GW. Accumulation of apoptosis-insensitive human bone marrow-mesenchymal stromal cells after long-term expansion. Cell Biochem Funct. 2016;34(5):310–6.  https://doi.org/10.1002/cbf.3191.CrossRefPubMedGoogle Scholar
  16. 16.
    Yagi H, Tan J, Tuan RS. Polyphenols suppress hydrogen peroxide-induced oxidative stress in human bone-marrow derived mesenchymal stem cells. J Cell Biochem. 2013;114(5):1163–73.  https://doi.org/10.1002/jcb.24459.CrossRefPubMedGoogle Scholar
  17. 17.
    Ksiazek K. A comprehensive review on mesenchymal stem cell growth and senescence. Rejuvenation Res. 2009;12(2):105–16.  https://doi.org/10.1089/rej.2009.0830.CrossRefPubMedGoogle Scholar
  18. 18.
    Choo KB, Tai L, Hymavathee KS, Wong CY, Nguyen PN, Huang CJ, Cheong SK, Kamarul T. Oxidative stress-induced premature senescence in wharton's jelly-derived mesenchymal stem cells. Int J Med Sci. 2014;11(11):1201–7.  https://doi.org/10.7150/ijms.8356.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. 2008;129(3):163–73.  https://doi.org/10.1016/j.mad.2007.12.002.CrossRefPubMedGoogle Scholar
  20. 20.
    Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev. 1991;12(2):151–80.  https://doi.org/10.1210/edrv-12-2-151.CrossRefPubMedGoogle Scholar
  21. 21.
    Acuna-Castroviejo D, Escames G, Venegas C, Diaz-Casado ME, Lima-Cabello E, Lopez LC, Rosales-Corral S, Tan DX, Reiter RJ. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014;71(16):2997–3025.  https://doi.org/10.1007/s00018-014-1579-2.CrossRefPubMedGoogle Scholar
  22. 22.
    Calvo JR, Gonzalez-Yanes C, Maldonado MD. The role of melatonin in the cells of the innate immunity: a review. J Pineal Res. 2013;55(2):103–20.  https://doi.org/10.1111/jpi.12075.CrossRefPubMedGoogle Scholar
  23. 23.
    Ma Y, Feng Q, Ma J, Feng Z, Zhan M, Ouyang L, Mu S, Liu B, Jiang Z, Jia Y, et al. Melatonin ameliorates injury and specific responses of ischemic striatal neurons in rats. J Histochem Cytochem. 2013;61(8):591–605.  https://doi.org/10.1369/0022155413492159.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Hosseinzadeh A, Kamrava SK, Joghataei MT, Darabi R, Shakeri-Zadeh A, Shahriari M, Reiter RJ, Ghaznavi H, Mehrzadi S. Apoptosis signaling pathways in osteoarthritis and possible protective role of melatonin. J Pineal Res. 2016;61(4):411–25.  https://doi.org/10.1111/jpi.12362.CrossRefPubMedGoogle Scholar
  25. 25.
    Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, Reiter RJ. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36(1):1–9.CrossRefGoogle Scholar
  26. 26.
    Karasek M, Winczyk K. Melatonin in humans. J Physiol Pharmacol. 2006;57(Suppl 5):19–39.PubMedGoogle Scholar
  27. 27.
    Reiter RJ, Tan DX, Rosales-Corral S, Manchester LC. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev Med Chem. 2013;13(3):373–84.PubMedGoogle Scholar
  28. 28.
    Tan DX, Manchester LC, Liu X, Rosales-Corral SA, Acuna-Castroviejo D, Reiter RJ. Mitochondria and chloroplasts as the original sites of melatonin synthesis: a hypothesis related to melatonin’s primary function and evolution in eukaryotes. J Pineal Res. 2013;54(2):127–38.  https://doi.org/10.1111/jpi.12026.CrossRefPubMedGoogle Scholar
  29. 29.
    Martin M, Macias M, Escames G, Reiter RJ, Agapito MT, Ortiz GG, Acuna-Castroviejo D. Melatonin-induced increased activity of the respiratory chain complexes i and iv can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res. 2000;28(4):242–8.CrossRefGoogle Scholar
  30. 30.
    Venegas C, Garcia JA, Escames G, Ortiz F, Lopez A, Doerrier C, Garcia-Corzo L, Lopez LC, Reiter RJ, Acuna-Castroviejo D. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res. 2012;52(2):217–27.  https://doi.org/10.1111/j.1600-079X.2011.00931.x.CrossRefPubMedGoogle Scholar
  31. 31.
    Acuna Castroviejo D, Lopez LC, Escames G, Lopez A, Garcia JA, Reiter RJ. Melatonin-mitochondria interplay in health and disease. Curr Top Med Chem. 2011;11(2):221–40.CrossRefGoogle Scholar
  32. 32.
    Zhang H, Liu D, Wang X, Chen X, Long Y, Chai W, Zhou X, Rui X, Zhang Q, Wang H, et al. Melatonin improved rat cardiac mitochondria and survival rate in septic heart injury. J Pineal Res. 2013;55(1):1–6.  https://doi.org/10.1111/jpi.12033.CrossRefPubMedGoogle Scholar
  33. 33.
    Song N, Kim AJ, Kim HJ, Jee HJ, Kim M, Yoo YH, Yun J. Melatonin suppresses doxorubicin-induced premature senescence of a549 lung cancer cells by ameliorating mitochondrial dysfunction. J Pineal Res. 2012;53(4):335–43.  https://doi.org/10.1111/j.1600-079X.2012.01003.x.CrossRefPubMedGoogle Scholar
  34. 34.
    Petrosillo G, Fattoretti P, Matera M, Ruggiero FM, Bertoni-Freddari C, Paradies G. Melatonin prevents age-related mitochondrial dysfunction in rat brain via cardiolipin protection. Rejuvenation Res. 2008;11(5):935–43.  https://doi.org/10.1089/rej.2008.0772.CrossRefPubMedGoogle Scholar
  35. 35.
    Acuna-Castroviejo D, Carretero M, Doerrier C, Lopez LC, Garcia-Corzo L, Tresguerres JA, Escames G. Melatonin protects lung mitochondria from aging. Age (Dordr). 2012;34(3):681–92.  https://doi.org/10.1007/s11357-011-9267-8.CrossRefGoogle Scholar
  36. 36.
    Acuna Castroviejo D, Escames G, Carazo A, Leon J, Khaldy H, Reiter RJ. Melatonin, mitochondrial homeostasis and mitochondrial-related diseases. Curr Top Med Chem. 2002;2(2):133–51.CrossRefGoogle Scholar
  37. 37.
    Jou MJ. Melatonin preserves the transient mitochondrial permeability transition for protection during mitochondrial ca(2+) stress in astrocyte. J Pineal Res. 2011;50(4):427–35.  https://doi.org/10.1111/j.1600-079X.2011.00861.x.CrossRefPubMedGoogle Scholar
  38. 38.
    Pablos MI, Reiter RJ, Ortiz GG, Guerrero JM, Agapito MT, Chuang JI, Sewerynek E. Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light. Neurochem Int. 1998;32(1):69–75.CrossRefGoogle Scholar
  39. 39.
    Barlow-Walden LR, Reiter RJ, Abe M, Pablos M, Menendez-Pelaez A, Chen LD, Poeggeler B. Melatonin stimulates brain glutathione peroxidase activity. Neurochem Int. 1995;26(5):497–502.CrossRefGoogle Scholar
  40. 40.
    Benitez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res. 2006;40(1):1–9.  https://doi.org/10.1111/j.1600-079X.2005.00282.x.CrossRefPubMedGoogle Scholar
  41. 41.
    Dubocovich ML, Markowska M. Functional mt1 and mt2 melatonin receptors in mammals. Endocrine. 2005;27(2):101–10.  https://doi.org/10.1385/endo:27:2:101.CrossRefPubMedGoogle Scholar
  42. 42.
    Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol. 2012;351(2):152–66.  https://doi.org/10.1016/j.mce.2012.01.004.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Reiter RJ, Tan DX, Fuentes-Broto L. Melatonin: a multitasking molecule. Prog Brain Res. 2010;181:127–51.  https://doi.org/10.1016/s0079-6123(08)81008-4.CrossRefPubMedGoogle Scholar
  44. 44.
    Kaneko Y, Hayashi T, Yu S, Tajiri N, Bae EC, Solomita MA, Chheda SH, Weinbren NL, Parolini O, Borlongan CV. Human amniotic epithelial cells express melatonin receptor mt1, but not melatonin receptor mt2: a new perspective to neuroprotection. J Pineal Res. 2011;50(3):272–80.  https://doi.org/10.1111/j.1600-079X.2010.00837.x.CrossRefPubMedGoogle Scholar
  45. 45.
    Chen C, Xu C, Zhou T, Gao B, Zhou H, Zhang C, Huang D, Su P. Abnormal osteogenic and chondrogenic differentiation of human mesenchymal stem cells from patients with adolescent idiopathic scoliosis in response to melatonin. Mol Med Rep. 2016;14(2):1201–9.  https://doi.org/10.3892/mmr.2016.5384.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res. 2011;51(1):1–16.  https://doi.org/10.1111/j.1600-079X.2011.00916.x.CrossRefPubMedGoogle Scholar
  47. 47.
    Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res. 2013;54(3):245–57.  https://doi.org/10.1111/jpi.12010.CrossRefPubMedGoogle Scholar
  48. 48.
    Reiter RJ, Tan DX, Terron MP, Flores LJ, Czarnocki Z. Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochim Pol. 2007;54(1):1–9.PubMedGoogle Scholar
  49. 49.
    Zhang L, Su P, Xu C, Chen C, Liang A, Du K, Peng Y, Huang D. Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing ppargamma expression and enhancing runx2 expression. J Pineal Res. 2010;49(4):364–72.  https://doi.org/10.1111/j.1600-079X.2010.00803.x.CrossRefPubMedGoogle Scholar
  50. 50.
    Radio NM, Doctor JS, Witt-Enderby PA. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via mt2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. J Pineal Res. 2006;40(4):332–42.  https://doi.org/10.1111/j.1600-079X.2006.00318.x.CrossRefPubMedGoogle Scholar
  51. 51.
    Hardeland R. Melatonin and synthetic melatoninergic agonists in psychiatric and age-associated disorders: successful and unsuccessful approaches. Curr Pharm Des. 2016;22(8):1086–101.CrossRefGoogle Scholar
  52. 52.
    Liu X, Gong Y, Xiong K, Ye Y, Xiong Y, Zhuang Z, Luo Y, Jiang Q, He F. Melatonin mediates protective effects on inflammatory response induced by interleukin-1 beta in human mesenchymal stem cells. J Pineal Res. 2013;55(1):14–25.  https://doi.org/10.1111/jpi.12045.CrossRefPubMedGoogle Scholar
  53. 53.
    Yun SP, Han YS, Lee JH, Kim SM, Lee SH. Melatonin rescues mesenchymal stem cells from senescence induced by the uremic toxin p-cresol via inhibiting mtor-dependent autophagy. Biomol Ther (Seoul). 2018;26(4):389–98.  https://doi.org/10.4062/biomolther.2017.071.CrossRefGoogle Scholar
  54. 54.
    Yang Y, Fan C, Deng C, Zhao L, Hu W, Di S, Ma Z, Zhang Y, Qin Z, Jin Z, et al. Melatonin reverses flow shear stress-induced injury in bone marrow mesenchymal stem cells via activation of amp-activated protein kinase signaling. J Pineal Res. 2016;60(2):228–41.  https://doi.org/10.1111/jpi.12306.CrossRefPubMedGoogle Scholar
  55. 55.
    Lee JH, Han YS, Lee SH. Potentiation of biological effects of mesenchymal stem cells in ischemic conditions by melatonin via upregulation of cellular prion protein expression. J Pineal Res. 2017;62(2).  https://doi.org/10.1111/jpi.12385.
  56. 56.
    Wang F, Zhou H, Du Z, Chen X, Zhu F, Wang Z, Zhang Y, Lin L, Qian M, Zhang X, et al. Cytoprotective effect of melatonin against hypoxia/serum deprivation-induced cell death of bone marrow mesenchymal stem cells in vitro. Eur J Pharmacol. 2015;748:157–65.  https://doi.org/10.1016/j.ejphar.2014.09.033.CrossRefPubMedGoogle Scholar
  57. 57.
    Mias C, Trouche E, Seguelas MH, Calcagno F, Dignat-George F, Sabatier F, Piercecchi-Marti MD, Daniel L, Bianchi P, Calise D, et al. Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells. 2008;26(7):1749–57.  https://doi.org/10.1634/stemcells.2007-1000.CrossRefPubMedGoogle Scholar
  58. 58.
    Wang FW, Wang Z, Zhang YM, Du ZX, Zhang XL, Liu Q, Guo YJ, Li XG, Hao AJ. Protective effect of melatonin on bone marrow mesenchymal stem cells against hydrogen peroxide-induced apoptosis in vitro. J Cell Biochem. 2013;114(10):2346–55.  https://doi.org/10.1002/jcb.24582.CrossRefPubMedGoogle Scholar
  59. 59.
    Zhou L, Chen X, Liu T, Gong Y, Chen S, Pan G, Cui W, Luo ZP, Pei M, Yang H, et al. Melatonin reverses h2 o2 -induced premature senescence in mesenchymal stem cells via the sirt1-dependent pathway. J Pineal Res. 2015;59(2):190–205.  https://doi.org/10.1111/jpi.12250.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Sethi S, Radio NM, Kotlarczyk MP, Chen CT, Wei YH, Jockers R, Witt-Enderby PA. Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. J Pineal Res. 2010;49(3):222–38.  https://doi.org/10.1111/j.1600-079X.2010.00784.x.CrossRefPubMedGoogle Scholar
  61. 61.
    Yang F, Yang L, Li Y, Yan G, Feng C, Liu T, Gong R, Yuan Y, Wang N, Idiiatullina E, et al. Melatonin protects bone marrow mesenchymal stem cells against iron overload-induced aberrant differentiation and senescence. J Pineal Res. 2017;63(3).  https://doi.org/10.1111/jpi.12422.
  62. 62.
    Rhee YH, Ahn JC. Melatonin attenuated adipogenesis through reduction of the CCAAT/enhancer binding protein beta by regulating the glycogen synthase 3 beta in human mesenchymal stem cells. J Physiol Biochem. 2016;72(2):145–55.  https://doi.org/10.1007/s13105-015-0463-3.CrossRefPubMedGoogle Scholar
  63. 63.
    Gao W, Lin M, Liang A, Zhang L, Chen C, Liang G, Xu C, Peng Y, Huang D, Su P. Melatonin enhances chondrogenic differentiation of human mesenchymal stem cells. J Pineal Res. 2014;56(1):62–70.  https://doi.org/10.1111/jpi.12098.CrossRefPubMedGoogle Scholar
  64. 64.
    Gao B, Gao W, Wu Z, Zhou T, Qiu X, Wang X, Lian C, Peng Y, Liang A, Qiu J, et al. Melatonin rescued interleukin 1beta-impaired chondrogenesis of human mesenchymal stem cells. Stem Cell Res Ther. 2018;9(1):162.  https://doi.org/10.1186/s13287-018-0892-3.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Liu X, Xu Y, Chen S, Tan Z, Xiong K, Li Y, Ye Y, Luo ZP, He F, Gong Y. Rescue of proinflammatory cytokine-inhibited chondrogenesis by the antiarthritic effect of melatonin in synovium mesenchymal stem cells via suppression of reactive oxygen species and matrix metalloproteinases. Free Radic Biol Med. 2014;68:234–46.  https://doi.org/10.1016/j.freeradbiomed.2013.12.012.CrossRefPubMedGoogle Scholar
  66. 66.
    Chang CL, Sung PH, Sun CK, Chen CH, Chiang HJ, Huang TH, Chen YL, Zhen YY, Chai HT, Chung SY, et al. Protective effect of melatonin-supported adipose-derived mesenchymal stem cells against small bowel ischemia-reperfusion injury in rat. J Pineal Res. 2015;59(2):206–20.  https://doi.org/10.1111/jpi.12251.CrossRefPubMedGoogle Scholar
  67. 67.
    Chen YT, Chiang HJ, Chen CH, Sung PH, Lee FY, Tsai TH, Chang CL, Chen HH, Sun CK, Leu S, et al. Melatonin treatment further improves adipose-derived mesenchymal stem cell therapy for acute interstitial cystitis in rat. J Pineal Res. 2014;57(3):248–61.  https://doi.org/10.1111/jpi.12164.CrossRefPubMedGoogle Scholar
  68. 68.
    Rashed LA, Elattar S, Eltablawy N, Ashour H, Mohamed L, El-Esawy Y. Mesenchymal stem cells pretreated with melatonin ameliorate kidney functions in a rat model of diabetic nephropathy. Biochem Cell Biol. 2018.  https://doi.org/10.1139/bcb-2017-0230.
  69. 69.
    Kosovrasti VY, Lukashev D, Nechev LV, Amiji MM. Novel rna interference-based therapies for sepsis. Expert Opin Biol Ther. 2014;14(4):419–35.  https://doi.org/10.1517/14712598.2014.875524.CrossRefPubMedGoogle Scholar
  70. 70.
    Zhang L, Zhang J, Ling Y, Chen C, Liang A, Peng Y, Chang H, Su P, Huang D. Sustained release of melatonin from poly (lactic-co-glycolic acid) (plga) microspheres to induce osteogenesis of human mesenchymal stem cells in vitro. J Pineal Res. 2013;54(1):24–32.  https://doi.org/10.1111/j.1600-079X.2012.01016.x.CrossRefPubMedGoogle Scholar
  71. 71.
    Clafshenkel WP, Rutkowski JL, Palchesko RN, Romeo JD, McGowan KA, Gawalt ES, Witt-Enderby PA. A novel calcium aluminate-melatonin scaffold enhances bone regeneration within a calvarial defect. J Pineal Res. 2012;53(2):206–18.  https://doi.org/10.1111/j.1600-079X.2012.00989.x.CrossRefPubMedGoogle Scholar
  72. 72.
    Lai M, Jin Z, Tang Q, Lu M. Sustained release of melatonin from tio2 nanotubes for modulating osteogenic differentiation of mesenchymal stem cells in vitro. J Biomater Sci Polym Ed. 2017;28(15):1651–64.  https://doi.org/10.1080/09205063.2017.1342334.CrossRefPubMedGoogle Scholar
  73. 73.
    Ma Q, Yang J, Huang X, Guo W, Li S, Zhou H, Li J, Cao F, Chen Y. Poly(lactide-co-glycolide)-monomethoxy-poly-(polyethylene glycol) nanoparticles loaded with melatonin protect adipose-derived stem cells transplanted in infarcted heart tissue. Stem Cells. 2018;36(4):540–50.  https://doi.org/10.1002/stem.2777.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, School of Medicine, First Affiliated HospitalZhejiang UniversityZhejiangPeople’s Republic of China

Personalised recommendations